07Jan/14

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology … – News-Medical.net

January 7, 2014Antibodiesadmin

Memorial Sloan-Kettering to use Sutro’s cell-free protein synthesis technology …
News-Medical.net
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with …
Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to …PR Newswire (press release)
Memorial Sloan-Kettering to Use Sutro Technology for Neuroblastoma ResearchGenetic Engineering News

all 7 news articles »

07Jan/14

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to … – PR Newswire (press release)

January 7, 2014Antibodiesadmin

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to …PR Newswire (press release)SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ — Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, in…

07Jan/14

Research and Markets: Monoclonal Antibodies Market in Gastric and … – The Herald | HeraldOnline.com (press release)

January 7, 2014Antibodiesadmin

Research and Markets: Monoclonal Antibodies Market in Gastric and …The Herald | HeraldOnline.com (press release)Gastric and esophageal cancers are two similar, overlapping groups of rare diseases, with their respective prevalence populations in the t…

07Jan/14

Research and Markets: Monoclonal Antibodies Market in Gastric and … – Business Wire (press release)

January 7, 2014Antibodiesadmin

Research and Markets: Monoclonal Antibodies Market in Gastric and …Business Wire (press release)Gastric and esophageal cancers are two similar, overlapping groups of rare diseases, with their respective prevalence populations in the top eight markets…

07Jan/14

Billionaire's Institute Donates $90 Million to Stanford – Patch.com

January 7, 2014Monoclonal Anti-CD20 Antibodiesadmin

Billionaire’s Institute Donates $90 Million to Stanford
Patch.com
Just recently, Weissman and his colleagues reported in the journal Science that this protein works particularly well when used in combination with other known anti-cancer agents, such as rituximab (a lymphoma drug) and trastuzumab, also known as …

and more »

06Jan/14

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach … – PR Web (press release)

January 6, 2014Antibodiesadmin

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach …
PR Web (press release)
In-demand research study “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” worked out by GBI Research has been recently published …
Research and Markets: Global Monoclonal Antibodies Pipeline AnalysisBusiness Wire (press release)

all 3 news articles »

06Jan/14

Induction chemotherapy did not improve outcomes in HNSCC – Healio

January 6, 2014Monoclonal Anti-CD20 Antibodiesadmin

Induction chemotherapy did not improve outcomes in HNSCCHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic…

06Jan/14

Stanford shares in $540 million gift from Ludwig Cancer Research – Stanford University News

January 6, 2014Monoclonal Anti-CD20 Antibodiesadmin

Stanford University NewsStanford shares in $540 million gift from Ludwig Cancer ResearchStanford University NewsJust recently, Weissman and his colleagues reported in the journal Science that this protein works particularly well when used in combinatio…

06Jan/14

PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from … – MarketWatch

January 6, 2014Monoclonal Anti-CD20 Antibodiesadmin

Drug Discovery & Development

PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from …
MarketWatch
… showing PIXUVRI’s cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line …
UK’s NICE Issues Final Appraisal Determination on CTI Lymphoma DrugDrug Discovery & Development
Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In …Seeking Alpha

all 22 news articles »

06Jan/14

Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In … – Seeking Alpha

January 6, 2014Monoclonal Anti-CD20 Antibodiesadmin

Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In …Seeking AlphaThe company is currently accruing patients into this study, which will compare Pixantrone and rituximab with gemcitabine and rituximab in the setting of aggre…

Category Archives: Antibodies